8-K/A: DNA X, Inc. Amends 8-K, Updates Equity for Nasdaq Compliance

DNA X, Inc. filed an 8-K/A amendment to its previous filing, providing updated pro forma stockholders' equity figures to demonstrate compliance with Nasdaq's minimum equity requirement following a recent financing transaction.

Summary

• DNA X, Inc. has filed an amendment (8-K/A) to its prior Form 8-K report dated July 2, 2026.
• This amendment updates disclosures related to unregistered sales of equity securities, material modifications to security holder rights, and amendments to articles of incorporation or bylaws.
• On July 8, 2026, the company sold 929,864 shares of Series B Preferred Stock for $2.5 million in cash and the cancellation of $3.1 million of convertible promissory note debt.
• The company anticipates completing the sale of an additional 416,667 shares by August 14, 2026.
• A Certificate of Designation for the Series B Preferred Stock was filed with the Secretary of State of Delaware on July 6, 2026.
• Based on these transactions, the company believes its pro forma stockholders' equity exceeds the $2.5 million requirement for continued listing on The Nasdaq Capital Market.
• The company is awaiting Nasdaq's formal confirmation of compliance with the minimum stockholders' equity rule.
• Pro forma unaudited stockholders' equity as of July 9, 2026, is estimated at $3,798,000, reflecting the completed transactions but excluding proceeds from the anticipated second closing.
• The pro forma information is based on management's current estimates and is for illustrative purposes only.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as the company is taking necessary steps to address its listing requirements, but the outcome is still pending Nasdaq's formal approval.

Positives

• The company has successfully raised $2.5 million in cash and converted $3.1 million in debt through the sale of Series B Preferred Stock.
• The pro forma stockholders' equity is estimated to be $3,798,000 as of July 9, 2026, which is expected to meet Nasdaq's minimum equity requirement for continued listing.
• The company is actively working towards regaining compliance with Nasdaq listing standards.

Negatives

• The company reported a net loss of $1,530,000 in Q2 2026 and an estimated net loss of $147,000 as of July 9, 2026.
• The company's beginning stockholders' equity was negative, standing at $(983,000) at the start of Q2 2026 and $(1,550,000) at the start of July 2026.
• The company is still awaiting Nasdaq's formal determination of compliance, indicating a degree of uncertainty regarding its listing status.

Risks

• The company's ability to maintain its listing on The Nasdaq Capital Market is contingent on Nasdaq's formal determination of compliance with the minimum stockholders' equity rule.
• Forward-looking statements are subject to a high degree of uncertainty and risk, including those described in the company's Form 10-K filed on April 15, 2026.
• There is a risk that the anticipated second closing of the Purchase Agreement may not be consummated by August 14, 2026.

Future Outlook

The company expects to consummate the sale of the remaining subscribed shares by August 14, 2026. The company is awaiting Nasdaq's formal determination regarding its compliance with the minimum stockholders' equity rule and intends to provide an update upon receipt.

Management Comments

• The Company believes it has stockholders equity in excess of the $2.5 million stockholders equity requirement for continued listing on The Nasdaq Capital Market.
• The pro forma information is based on managements current estimates and assumptions, is presented for illustrative purposes only, and should not be regarded as indicative of the Companys future financial condition or results of operations.

Industry Context

StockSavvy.ai notes that this filing is typical for companies facing potential delisting from major exchanges due to insufficient equity. The proactive steps taken by DNA X, Inc. to raise capital and restructure debt are crucial for maintaining its listing and access to public markets.

Corporate Governance

Stakeholder Impact

• Shareholders: The successful compliance with Nasdaq listing requirements is crucial for maintaining the liquidity and value of their investment. Failure to comply could lead to delisting, negatively impacting share price.
• Creditors: The conversion of convertible promissory notes into equity reduces outstanding debt, potentially improving the company's credit profile.
• Management: The focus on meeting listing requirements indicates ongoing efforts to stabilize and grow the company, which is a primary responsibility of management.

Next Steps

• Await Nasdaq's formal determination regarding compliance with the minimum stockholders' equity rule.
• Provide an update to the market upon receipt of Nasdaq's determination.
• Consummate the sale of the remaining 416,667 shares of Series B Preferred Stock by August 14, 2026.

Key Dates

Recommendation

The company is taking necessary steps to address its Nasdaq listing compliance, which is a positive development. However, the outcome is still pending Nasdaq's formal approval, and the company continues to incur losses. Therefore, a 'hold' recommendation is appropriate pending confirmation of listing status and further operational improvements.

Keywords

DNA X, Inc., 8-K/A, Nasdaq Capital Market, Stockholders Equity, Series B Preferred Stock, Convertible Promissory Note, Financing, Listing Compliance, SEC Filing, Amendment